NCT02796352 - A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 16, 2017

Study Completion Date

April 30, 2017

Conditions

Melanoma

Interventions

DRUG

High dose bolus interleukin-2 (HD IL2)

"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2."

Trial Locations (1)

15232

University of Pittsburgh Medical Center- Hillman Cancer Center, Pittsburgh